See more : Topre Corporation (5975.T) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclacel Pharmaceuticals, Inc. (CYCCP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclacel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Cellectis S.A. (ALCLS.PA) Income Statement Analysis – Financial Results
- Rockcliff Metals Corporation (RCLF.CN) Income Statement Analysis – Financial Results
- Nauticus Robotics, Inc. (KITT) Income Statement Analysis – Financial Results
- Organto Foods Inc. (OGO.V) Income Statement Analysis – Financial Results
- Nextensa NV/SA (NEXTA.BR) Income Statement Analysis – Financial Results
Cyclacel Pharmaceuticals, Inc. (CYCCP)
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 150.00K | 0.00 | 843.00K | 1.94M | 1.73M | 1.08M | 69.00K | 699.00K | 686.00K | 911.00K | 877.00K | 129.00K | 387.00K | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Cost of Revenue | 0.00 | 32.00K | 43.00K | 20.00K | 20.00K | 4.33M | 32.00K | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 360.00K | 418.00K | 545.00K | 429.00K | 19.57M | 21.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 420.00K | -32.00K | -43.00K | -20.00K | -20.00K | -4.18M | -32.00K | -8.63M | -10.44M | -16.54M | -10.19M | -6.52M | 339.00K | 268.00K | 366.00K | 448.00K | -19.44M | -20.82M | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,784.67% | 0.00% | -1,024.20% | -536.93% | -954.04% | -940.31% | -9,453.62% | 48.50% | 39.07% | 40.18% | 51.08% | -15,069.77% | -5,379.33% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 19.16M | 20.27M | 15.48M | 4.76M | 4.66M | 4.33M | 4.24M | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 9.21M | 6.41M | 9.77M | 18.87M | 10.00K | 231.00K | 13.77M | 19.70M | 13.69M | 14.66M | 14.70M | 11.26M |
| General & Administrative | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.73M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 0.00 | 5.20M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.75M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 4.98M | 5.20M | 2.40M |
| Other Expenses | 0.00 | 1.30M | 144.00K | 891.00K | 231.00K | 682.00K | 949.00K | 0.00 | 12.13K | 0.00 | 0.00 | 0.00 | 360.00K | 6.73M | 911.00K | 8.85M | 21.11M | 0.00 | 7.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 16.73M | 16.53M | 18.30M | 34.22M | 11.54M | 12.32M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Cost & Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 17.09M | 16.95M | 18.85M | 34.65M | 31.11M | 33.52M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Interest Income | 266.00K | 210.00K | 16.00K | 42.00K | 224.00K | 331.00K | 118.00K | 37.00K | 9.00K | 6.00K | 13.00K | 22.00K | 45.00K | 37.00K | 102.00K | 1.38M | 3.55M | 2.33M | 960.00K | 421.00K | 149.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.00K | 177.00K | 318.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 31.00K | 32.00K | 43.00K | 20.00K | 20.00K | 29.00K | 32.00K | 133.00K | 210.00K | 174.00K | 70.00K | 60.00K | 241.00K | 457.00K | 668.00K | 1.86M | 299.00K | 1.10M | 1.55M | 1.31M | 929.00K | 0.00 | 0.00 | -621.00K |
| EBITDA | -25.42M | -27.62M | -22.69M | -10.62M | -9.66M | -9.52M | -9.46M | -14.02M | -15.96M | -22.26M | -17.90M | -15.05M | -15.57M | -16.18M | -19.67M | -39.96M | -24.75M | -30.13M | -19.45M | -24.48M | -16.91M | -19.64M | -19.88M | -14.18M |
| EBITDA Ratio | -6,052.86% | 0.00% | 0.00% | 0.00% | 0.00% | -6,305.33% | 0.00% | -1,718.74% | -817.13% | -1,281.37% | -1,656.92% | -21,782.61% | -2,303.58% | -2,299.13% | -1,957.85% | -3,481.53% | -24,993.80% | -8,165.89% | -2,551.54% | -39,482.26% | -9,945.29% | 0.00% | -66,250.00% | -14,472.45% |
| Operating Income | -25.45M | -27.66M | -22.94M | -10.64M | -9.68M | -9.55M | -9.49M | -14.15M | -16.17M | -22.44M | -17.97M | -15.10M | -16.39M | -16.27M | -18.30M | -42.20M | -32.54M | -33.36M | -29.69M | -26.51M | -17.84M | -19.64M | -19.88M | -13.56M |
| Operating Income Ratio | -6,060.24% | 0.00% | 0.00% | 0.00% | 0.00% | -6,365.33% | 0.00% | -1,678.53% | -831.79% | -1,293.94% | -1,658.12% | -21,888.41% | -2,344.49% | -2,371.14% | -2,009.22% | -4,811.63% | -25,222.48% | -8,620.67% | -3,651.91% | -42,761.29% | -10,492.35% | 0.00% | -66,250.00% | -13,838.78% |
| Total Other Income/Expenses | -98.00K | 1.74M | 204.00K | 955.00K | 556.00K | 923.00K | 1.03M | 376.00K | -316.00K | -212.00K | 6.09M | -4.00K | 580.00K | 245.00K | -2.58M | -8.36M | 4.89M | 1.63M | 827.00K | 1.31M | -1.00K | 0.00 | 19.88M | 621.00K |
| Income Before Tax | -25.55M | -25.92M | -22.73M | -9.68M | -9.13M | -8.63M | -8.46M | -13.77M | -16.49M | -22.65M | -11.88M | -15.11M | -15.81M | -16.68M | -20.52M | -42.14M | -26.09M | -31.50M | -37.09M | -27.24M | -17.84M | 0.00 | 0.00 | -12.94M |
| Income Before Tax Ratio | -6,083.57% | 0.00% | 0.00% | 0.00% | 0.00% | -5,750.00% | 0.00% | -1,633.93% | -848.05% | -1,306.17% | -1,095.94% | -21,894.20% | -2,261.52% | -2,431.20% | -2,252.25% | -4,804.45% | -20,227.91% | -8,140.31% | -4,561.87% | -43,933.87% | -10,492.94% | 0.00% | 0.00% | -13,205.10% |
| Income Tax Expense | -3.00M | -4.72M | -3.85M | -1.24M | -1.30M | -1.34M | -993.00K | -1.98M | -2.14M | -3.24M | -1.67M | -1.35M | -565.00K | -657.00K | -948.00K | -1.75M | -2.04M | -2.25M | -274.00K | 13.08M | 620.00K | 19.45M | 19.51M | 0.00 |
| Net Income | -22.56M | -21.20M | -18.89M | -8.45M | -7.83M | -7.29M | -7.47M | -11.79M | -14.34M | -19.39M | -10.15M | -13.19M | -15.24M | -16.02M | -19.57M | -40.39M | -24.05M | -29.26M | -29.42M | -39.59M | -18.46M | -19.45M | -19.51M | -12.94M |
| Net Income Ratio | -5,370.24% | 0.00% | 0.00% | 0.00% | 0.00% | -4,858.67% | 0.00% | -1,398.70% | -737.76% | -1,118.05% | -936.62% | -19,110.14% | -2,180.69% | -2,335.42% | -2,148.19% | -4,605.02% | -18,645.74% | -7,560.21% | -3,618.20% | -63,851.61% | -10,857.06% | 0.00% | -65,040.00% | -13,205.10% |
| EPS | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.91K | -4.92K | -3.27K |
| EPS Diluted | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.21K | -4.22K | -2.80K |
| Weighted Avg Shares Out | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 3.96K | 3.96K | 3.96K |
| Weighted Avg Shares Out (Dil) | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 4.62K | 4.62K | 4.62K |
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it is in the process of exploring and reviewing strategic...
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of...
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it has entered into a definitive agreement for the exercise...
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update.
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
BERKELEY HEIGHTS, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it received a written notice (the “Notice”) from The Nasdaq Stock...
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
- Patients are preselected for CDKN2A and/or CDKN2B abnormalities - - Safety and efficacy data to be reported at an upcoming oncology medical conference - BERKELEY HEIGHTS, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ:...
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will be featured as a presenting...
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
BERKELEY HEIGHTS, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company timely requested a hearing...
Source: https://incomestatements.info
Category: Stock Reports